Sensei Biotherapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Sensei Biotherapeutics generated cash of -$32,023,000, which is more than the previous year. Cash used in financing activities reached the amount of -$11,173,000 last year. Net change in cash is therefore -$4,784,000.
Cash Flow
| 2018 | -10.31M | -31K | 750K |
|---|---|---|---|
| 2019 | -8.57M | -53K | 8.22M |
| 2020 | -17.70M | -1.40M | 35.45M |
| 2021 | -30.25M | -143.11M | 163.94K |
| 2022 | -39.02M | 49.94M | -287K |
| 2023 | -32.02M | 38.41M | -11.17M |
SNSE Cash Flow Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 17.79M | 7.15M | 16.59M | 251K | 653K | 10.24M |
Operating activities | ||||||
Net income | -34.10M | -48.58M | -36.79M | -20.1M | -16.74M | -13.03M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 1.35M | 1.34M | 685K | 209K | 73K | 44K |
Stock-based compensation expense | 4.45M | 5.81M | 5.65M | 1.49M | 1.17M | 0 |
| Deferred income tax benefit | 4.45M | 5.81M | 5.65M | 1.49M | 1.17M | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -2.33M | 2.01M | -1.42M | 335K | 2.34M | 931K |
Cash generated by operating activities | -32.02M | -39.02M | -30.25M | -17.70M | -8.57M | -10.31M |
Investing activities | ||||||
Purchases Of Investments | -21.14M | -46.86M | -183.66M | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -180K | -321K | -2.02M | -1.20M | -53K | -31K |
Acquisitions Net | 0 | 15K | 318K | -197K | 0 | 0 |
Cash generated by investing activities | 38.41M | 49.94M | -143.11M | -1.40M | -53K | -31K |
Financing activities | ||||||
Common Stock Issued | 0 | 238K | 164.11M | 541K | 154K | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -10.38M | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -761K | -629K | -255 | -41K | 8.06M | 0 |
Cash used in financing activities | -11.17M | -287K | 163.94K | 35.45M | 8.22M | 750K |
Net Change In Cash | -4.78M | 10.63M | -9.43M | 16.34M | -402K | -9.59M |
Cash at end of period | 13.01M | 17.79M | 7.15M | 16.59M | 251K | 653K |
| Data source | Data source | Data source | Data source |